Tandem Diabetes Care (TNDM) Amortization of Deferred Charges (2013 - 2026)

Tandem Diabetes Care has reported Amortization of Deferred Charges for 13 years, with the latest figure at $576000.0 in Q1 2026.

• For the quarter ending Q1 2026, Amortization of Deferred Charges rose 14.06% year-over-year to $576000.0; the trailing twelve-month figure through Mar 2026 stood at $1.9 million (down 0.67% YoY), and the FY2025 full-year result was $1.9 million, down 10.96% from the prior year.
• Amortization of Deferred Charges for Q1 2026 stood at $576000.0, up from $446000.0 in the prior quarter.
• The five-year high for Amortization of Deferred Charges was $702000.0 in Q3 2023, with the low at $435000.0 in Q2 2024.
• Historically, Amortization of Deferred Charges has averaged $504000.0 across 5 years, with a median of $498000.0 in 2022.
• Annual changes were most pronounced in 2023 — Amortization of Deferred Charges soared 40.96% — and 2024, when it slipped 28.49%.
• Tandem Diabetes Care's Amortization of Deferred Charges stood at $501000.0 in 2022, then retreated by 1.6% to $493000.0 in 2023, then gained by 1.83% to $502000.0 in 2024, then slipped by 11.16% to $446000.0 in 2025, then climbed by 29.15% to $576000.0 in 2026.
• The last three Amortization of Deferred Charges figures came in at $576000.0 (Q1 2026), $446000.0 (Q4 2025), and $444000.0 (Q3 2025), per Business Quant data.